54 results about "Human respiratory virus" patented technology

The invention relates to the field of prevention and treatment of respiratory diseases, and discloses a preparation method of a human respiratory syncytial virus preventive mRNA vaccine. The main components of the mRNA vaccine comprise mRNA for coding an antigen and lipid nanoparticles. According to the mRNA sequence provided by the invention, an independently researched and developed 5 'UTR / 3' UTR sequence and a codon optimization mode are adopted, and efficient translation of target protein can be realized. According to the mRNA vaccine provided by the invention, RSV F protein is selected as an antigen, and the RSV F protein sequence is optimally designed, so that stable pre-fusion conformation RSV F protein can be expressed, and after a mouse is immunized, the mouse can be induced to generate high-level RSV F protein specific binding antibody titer and neutralizing antibody titer.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Related to the field of prevention and treatment of respiratory diseases, and disclosed a method for preparing a preventive mRNA vaccine against human respiratory syncytial virus. In some embodiments, the mRNA vaccine comprises an antigen-encoding mRNA and lipid nanoparticles. In some embodiments, the mRNA sequence utilizes an improved 5'UTR / 3'UTR sequence and codon optimization methods for efficient translation of the target protein. In some embodiments, the mRNA vaccine expresses an RSV F protein that is used as an antigen, wherein the sequence of the RSV F protein is optimized to achieve stable RSV pre-F protein expression. After immunization, the mRNA vaccine induces high levels of RSV F protein-specific binding antibody titer and neutralizing antibody titer in mice.

The present invention relates to a viral strain derived from a human metapneumovirus (hMPV) strain having a genomic sequence represented by sequence SEQ ID NO: 1 wherein the genomic sequence comprises the following genetic modifications: (i) inactivating an endogenous gene encoding an SH protein and / or a G protein, and (ii) the presence of an exogenous sequence encoding at least one extracellular domain of an F protein of a human respiratory syncytial virus (hRSV), the domain is of a wild type or mutant.

This invention discloses the application of 2,4-di-tert-butylphenol in the preparation of anti-human respiratory syncytial virus (RSV) drugs, belonging to the field of biomedical technology. 2,4-Di-tert-butylphenol exhibits good anti-RSV effects both in vitro and in vivo. In vitro, it can inhibit viral infection of cells, and in vivo, it can alleviate lung damage caused by viral infection and reduce lung inflammation. This invention provides experimental evidence for the development of highly effective and safe anti-RSV drugs and also offers more drug options for their development.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present disclosure provides compositions comprising at least two messenger RNAs (mRNAs) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and / or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen, and methods of eliciting an immune response by administering said compositions.

Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which inhibit human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to pharmaceutical compositions comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to methods of treating a subject for HRSV or HMPV infection by administering a pharmaceutical composition comprising a compound of the present invention.

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K) L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

The invention relates to a human respiratory syncytial virus (hRSV) fusion F protein variant, a vaccine based on the human respiratory syncytial virus fusion F protein variant and application of the human respiratory syncytial virus fusion F protein variant. The hRSV fusion F protein variant (especially an mRNA vaccine based on the hRSV fusion F protein variant) can induce an organism to generate a high-level neutralizing antibody aiming at the respiratory syncytial virus, meanwhile, cellular immune response can be activated, dual activation of humoral immunity and cellular immunity is achieved, and the hRSV fusion F protein variant has cross protection efficacy on all subtypes of the hRSV. Therefore, a vaccine product based on the hRSV fusion F protein variant has important application value in clinical treatment and prevention and control of the respiratory syncytial virus.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The present disclosure relates to the technical field of gene drugs, and particularly relates to an immunological composition containing a human respiratory syncytial virus antigen, wherein the human respiratory syncytial virus (hRSV) antigen is a pre-fusion hRSV F protein.

The present disclosure relates to an immune composition comprising or encoding a human respiratory syncytial virus antigen, selected from the group consisting of a nucleic acid immune composition, a polypeptide immune composition or a viral immune composition.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The invention discloses a polypeptide inhibitor capable of effectively resisting respiratory tract RNA (Ribonucleic Acid) virus and application thereof. The TP series polypeptide provided by the invention has efficient and broad-spectrum antiviral activity. Therefore, a new strategy is provided for prevention and control of human respiratory viruses, and meanwhile, a new theoretical basis is provided for accelerating research and development of polypeptide small molecule drugs for resisting the respiratory viruses. The TP series polypeptide has a clear antiviral mechanism, can ensure the safety of application and the definition of an optimization approach, is convenient for later further development, improves the stability of a polypeptide drug, improves the administration mode of the polypeptide drug, and is expected to further expand the application range and effect of a polypeptide inhibitor in resisting respiratory tract RNA viruses.

The present disclosure provides compositions comprising at least two messenger RNAs (mRNA) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and / or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen; and methods of eliciting an immune response by administering the composition.

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

The present invention relates to formula (I): [Formula 1] JPEG2026513827000477.jpg3557 The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof that (I) inhibit inhibitors of human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to a pharmaceutical composition comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to a method for treating HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.